Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/50027| Title: | Drug interactions and bleeding complications with rivaroxaban compared to warfarin |
| Authors: | Cardona, Mark Wirth, Francesca Serracino-Inglott, Anthony Azzopardi, Lilian M. |
| Keywords: | Rivaroxaban Anticoagulants (Medicine) -- Complications -- Case studies Anticoagulants (Medicine) -- Malta -- Case studies Drug interactions Warfarin Cardiovascular Disease -- Chemotherapy |
| Issue Date: | 2017-09 |
| Publisher: | University of Malta. Department of Pharmacy |
| Citation: | Cardona, M., Wirth, F., Serracino-Inglott, A., & Azzopardi, L. M. (2017, September). Drug interactions and bleeding complications with rivaroxaban compared to warfarin. Poster session presented at the FIP Annual Conference, Seoul, Republic of Korea. |
| Abstract: | A poster presentation regarding drug interactions and bleeding complications with rivaroxaban compared to warfarin. Introduction: Compared to warfarin, the novel oral anticoagulant (NOAC) rivaroxaban has the advantages of a fixed dosing regimen with no need for INR monitoring and fewer potential drug-drug interactions (DDIs). However, there is conflicting evidence regarding bleeding complications. Aims: • To determine INR control for patients on warfarin; • To compare warfarin to rivaroxaban with respect to potential DDIs and incidence and severity of bleeding. |
| URI: | https://www.um.edu.mt/library/oar/handle/123456789/50027 |
| Appears in Collections: | Scholarly Works - FacM&SPha |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Drug_interactions_and_bleeding_complications_with_rivaroxaban_compared_to_warfarin_2017.pdf | 489.09 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.